The treatment of Graves' orbitopathy (GO) remains a diagnostic and therapeutic challenge for clinicians worldwide. The elimination of risk factors, such as encouraging smoking cessation and achieving euthyroidism, are the most important and usually sufficient treatment methods in most mild cases. A course of selenium may also be beneficial. High-dose systemic corticosteroid therapy remains the first-line therapy in moderate-to-severe orbitopathy; however in some patients such treatment may be insufficient. Radiotherapy for GO has been used for decades and is considered to be effective in active GO, although less than systemic corticosteroids. Unfortunately, there are only eight randomised studies that may be analysed to assess its true effectiveness and applicability. It has been indicated that radiotherapy affects mainly eye motility and soft tissue changes, with almost no influence on exophthalmos. The combination of these two therapies has proven to be even more effective than either treatment alone, especially in subjects with resistant or recurrent GO. Orbital radiotherapy seems to be a safe procedure with few adverse effects observed long after the therapy. It should be avoided in patients with retinopathy, due to diabetes mellitus and hypertension, and in young subjects (< 35 years old). Orbital radiotherapy, as a safe and generally effective second-line therapy, is used in some countries as a supporting method during the second course of systemic corticosteroid therapy, if the response to the first course is unsatisfactory. 
Introduction
The first full clinical description of Graves' disease (GD) was presented in 1835 by Dr Robert James Graves, although some researchers like Karl Adolph von Basedow had noted the characteristic coexistence of protruding eyes and an enlarged thyroid much earlier [1] . Over the decades, knowledge about this condition including symptoms, pathomechanism and treatment has greatly improved. This autoimmune disorder, mostly affecting the thyroid gland, is associated with the production of auto-antibodies binding with thyroid hormone receptor (TSHR). Circulating auto-antibodies stimulate receptors localised in the thyroid and extrathyroidal tissues. As
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a result, hypertrophy of the thyroid gland, orbital muscles and adipose tissue occurs, as well as an increase in thyroid hormones production and the stimulation of orbital fibroblasts to synthesise glycosaminoglycans (GAGs). The fully developed image of the disease involves usually hyperthyroidism, goitre, exophthalmos, and an increased level of anti-TSHR antibodies (TRAbs) [2, 3] .
The most common extrathyroidal manifestation of Graves' disease is orbitopathy (GO). Its current prevalence is 1.6 cases/million population/year in women and 0.29 cases/million population/year in men [4] . According to The European Group of Graves' Orbitopathy (EUGOGO), GO can be divided into three groups: sight-threatening, moderate-to-severe, and mild. The classification to the correct group and the type of applied treatment depends on the clinical symptoms and the patient's quality of life. With sight-threatening GO -patients with high risk of blindness (dysthyroid optic neuropathy) -an immediate treatment is needed. Moderate-to-severe GO features patients with a significantly decreased quality of life and presenting, for example, lid retraction ≥ 2 mm, soft tissue enlargement in an orbit, exophthalmos ≥ 3 mm and permanent or temporary diplopia. Mild GO features patients who do not present the features of moderate-to-severe GO, and the disease has only a minor impact on their quality of life.
The treatment of GO is multidisciplinary, depends on the phase of the disease, and generally includes normalisation of thyroid function, modification of risk factors (e.g. smoking), selenium supplementation, immunosuppressive and surgical treatment, radiotherapy, and finally the combination of these methods [3] .
The treatment of mild Graves' orbitopathy
Undoubtedly, the most important issue in the management of mild GO is the normalisation of thyroid function and the elimination of risk factors. With the proper treatment of hyperthyroidism, the activity of GO usually limits spontaneously [5] . The most important risk factor that should be modified is smoking. Smokers are not only 7-8 times more prone to develop Graves' disease, but also the severity and progression of orbitopathy seems to be increased. Moreover, smoking patients are less responsive to treatment than non-smokers [6, 7] . It has been reported that a course of selenium may be also beneficial, due to its natural antioxidative properties [8] . Some local measures such as artificial tears increase the patient's comfort of life as a symptomatic treatment for tearing and burning. About 15% of patients with mild orbitopathy will progress to the moderate or even the severe form of GO [9] . High TSH receptor antibodies titre and smoking are the strongest risk factors [10] .
The treatment of moderate-to-severe Graves' orbitopathy
Immunosuppressive and immunomodulatory treatment is reserved for patients with orbitopathy that has a significant impact on daily life and does not respond to the above mentioned management [11] . Treatment with corticosteroids is widely considered to be the most effective therapy in cases of moderate-to-severe GO. A positive response has been seen in up to 80% of patients [12, 13] . Nowadays, systemic intravenous treatment with prednisolone is the first-line treatment modality. The high-dose intravenous therapy shows a better clinical outcome and fewer accompanying side effects such as diabetes or weight gain, than highdose oral treatment [14] . The intravenous treatment is usually followed by oral or intramuscular steroids administration.
Another potential method of GO treatment is the use of somatostatin analogues. Since somatostatin receptors have been detected on orbital fibroblasts, it has been hypothesised that somatostatin analogues may improve the outcome of GO. This theory was supported by the observation that the activity of orbitopathy is proportional to the uptake visualised on OctreoScans. A few studies have attempted to evaluate the usefulness of this method, although the obtained results are not consistent [15] [16] [17] . Generally, the use of somatostatin analogues results in a slight decrease in activity score compared to a placebo, although no improvement in other GO symptoms has been observed [18] . Hence, somatostatin analogues are not used in the routine management of GO.
Prummel et al. conducted a study assessing the efficacy of cyclosporine, particularly in subjects with moderate-to-severe GO. Compared to prednisolone, cyclosporine presented poorer treatment efficacy. However, the group of patients who received both prednisolone and cyclosporine presented better eventual outcome than the subjects receiving only one of these medications. Hence, cyclosporine is usually used after corticosteroid treatment. The recommended doses are 3 to 5 mg/kg/day [3, 19, 20] .
If all conservative methods fail to stop GO progression, or the disease is sight-threatening, orbital decompression surgery should be considered. This surgery may be also performed for cosmetic correction of severe proptosis in patients in the non-active phase of the disease [21] .
The other method used in the treatment of GO is radiotherapy. The value of orbital irradiation remains
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controversial, and will be the major subject of this review.
Orbital radiotherapy -basic information
The first application of X-rays in 'orbitopathy after thyroidectomy' was described in 1913, when the case of a 36-year-old woman was reported, suffering from severe exophthalmos and symptoms of hyperthyroidism including weight loss, tachycardia and goitre. The patient was treated with belladonna, arsenic, digitalis, resection of cervical sympathetic nerves, lotions, and rest. Although the systemic signs and symptoms decreased, proptosis worsened, followed by keratitis, hypopyon and eventually right eye loss. Severing of the canthal tendons and tarsorrhaphy were used to prevent the same outcome in the remaining eye, however the sutures were too weak. The orbitopathy improved eventually, after X-ray treatment of the thyroid gland. The first described case of targeted orbit irradiation with X-rays was reported in 1936 by Thomas and Woods, who performed it to reduce the swelling in a patient with severe exophthalmos [22] . External radiotherapy as an important part of GO management was fully introduced more than 60 years ago. At first, the cause of the orbitopathy was established to be associated with hypothalamic dysfunction or pituitary factors, and as a consequence X-rays were directed on the hypothalamus and pituitary gland. Later, radiation was correctly applied to the orbital tissue. Firstly, the orthovoltage machine was used, than a linear accelerator was adapted [23, 24] .
Orbital radiotherapy is often considered as a secondline therapy in moderate-to-severe GO. This kind of treatment not only has nonspecific anti-inflammatory properties, but also affects lymphocytes that infiltrate the orbital space [23] . The orbital lymphocytes activity is suppressed and the helper/suppressor T lymphocyte ratio is altered [25] . Moreover, the low doses of radiation influence the orbital fibroblasts, that synthesise and secrete fewer GAGs [26] . The orbital radiotherapy results in the inactivation of the inflammatory process, causing irreversible fibrosis of the orbital tissues.
Orbital radiotherapy -efficacy
The proper assessment of the treatment efficacy in a case of orbital radiotherapy is very difficult, for many reasons. Firstly, most of the reported studies are retrospective and non-randomised. Randomised clinical trials are sparse and the studied groups are often very small. Secondly, there are many scales and different types of criteria to assess and compare the activity and severity of GO [3] . It seems even harder to objectively evaluate the response to treatment and general clinical outcome. What is more, various inclusion and exclusion criteria have been used. Finally, the radiotherapy regimen differs significantly between published studies.
Bearing all these conditions in mind, there are only eight randomised control trials in the available literature that can be analysed.
Three of these studies regard the efficacy of orbital radiotherapy compared to sham irradiation. Mourits et al. [27] reported the results of external beam irradiation versus sham irradiation in subjects with moderate-tosevere orbitopathy. A successful treatment outcome was observed in 18 of 30 (60%) irradiated patients, when only nine of 29 (31%) sham-irradiated patients experienced clinical improvement. The improvement was mostly observed in diplopia grade, while neither proptosis nor eyelid swelling was reduced. The authors concluded that this kind of therapy is efficient, but only to treat motility impairment. Gorman et al. [28] on the other hand showed no beneficial therapeutic effects of orbital radiotherapy compared to sham-irradiation. In this study, 42 patients with moderate-to-severe Graves's orbitopathy received orbital radiotherapy to only one orbit. After six months, the untreated orbit was irradiated while the other received sham-irradiation. No clinical or statistically significant difference in any of the outcome measures (volume of extraocular muscles and fat, range of ocular motility, area of diplopia fields, and eyelid aperture) was noted at six months. After 12 months, a slight improvement of marginal statistical significance was observed in muscle volume and proptosis in the first irradiated orbit. Prummel et al. [29] on the other hand demonstrated the effectiveness of orbital radiotherapy in the mild form of GO. After 12 months, the radiotherapy outcome was positive in 23 of 44 (52%) irradiated patients while only 12 of 44 (27%) sham-irradiated subjects experienced symptom improvement. The therapy was the most effective in the case of eye muscle motility and diplopia. Although the quality of life improved similarly in both groups, fewer irradiated patients needed further therapy (66% vs. 84%).
In conclusion, based on the presented research, generally orbital radiotherapy improves the symptoms of GO, mostly by increasing eye motility and decreasing the range of diplopia. The use of radiotherapy in cases of a mild form of orbitopathy seems effective, although it does not prevent the further progression of the disease. In our opinion, there are other safer and more effective treatment modalities for mild GO; orbital irradiation should be reserved for moderate-to-severe cases.
Some studies have evaluated the effectiveness of orbital radiotherapy compared to systemic glucocorticosteroid therapy. Bartalena et al. in 1983 [30] reported the first randomised trial concerning this issue. The study assessed the efficacy of systemic methylpredni-
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solone administration and the combined therapy (radiotherapy plus systemic methylprednisolone). It was indicated that both methods are valuable, although subjects receiving combined therapy presented better clinical outcome (33% -excellent response, 39% -good response, 25% -slight response, 3% -no response). What is more, the combined therapy was more effective in soft tissue involvement, newly developed eye motility impairment, and optic neuropathy. Proptosis and long-lasting ophtalmophlegia were significantly less responsive. In the research by Marcocci et al. [31] combined treatment of radiotherapy with either oral or intravenous methylprednisolone administration was used. In both groups, significant reductions in proptosis, diplopia and eyelid width were observed, with no statistically significant difference between the two groups. Both intravenous and oral administered corticosteroids were effective, but generally the intravenous route seemed more effective and better tolerated with fewer side-effects. The combined therapy of irradiation and steroids administration was also evaluated by Ng et al. [32] . In this study, the treatment with intravenous prednisolone was followed by oral prednisolone that was gradually tapered down. The group treated with both irradiation and glucocorticosteroids showed more beneficial effects (seven of eight patients) compared to patients treated only with systemic glucocorticosteroids (two of seven patients), and the beneficial outcome (improvement in soft tissue swelling, ocular motility and visual activity) was achieved earlier in the first group. The last randomised double-blind study concerning this issue was performed by Prummel et al. [13] The study enrolled 28 patients treated with a three-month course of oral prednisolone and sham irradiation, and 28 subjects treated with orbital radiotherapy and a placebo. The treatment outcome was defined as a change in the highest NOSPECS class. A successful outcome was noted in 14 patients treated with prednisolone (50%) and 13 irradiated subjects (46%). The improvement mostly involved better ocular motility (more pronounced in irradiated patients) and soft tissue changes improvement (more evident in prednisolone-treated subjects). Interestingly, adverse effects were more frequent in patients treated with prednisolone than irradiated subjects. There was no significant difference in the need for subsequent surgical treatment.
In conclusion, combined treatment with orbital irradiation and systemic glucocorticosteroid therapy is more effective than either treatment modality alone. Unfortunately, data regarding the synergistic effect of radiotherapy and intravenous steroid treatment is still sparse.
Unfortunately, there is only one randomised, single blind study that compares the efficacy and tolerability of three orbital radiotherapy protocols. Orbital radiotherapy was administered in patients with moderateto-severe GO either in 20 divided fractions of 1 Gray weekly over 20 weeks, or in 10 fractions of 1 Gray, and 2 Gray daily over 2 weeks. The same response rates were observed for both low and high doses of radiation, however the protocol of 1 Gray weekly was more effective and better tolerated than daily administration [33] . Good results of hypofractioned orbital radiotherapy in a protocol of 1 Gray over ten weeks was reported in a recent prospective, although not-randomised study [34] . To date, no specific recommendations have been drawn up and no optimal protocol has been determined.
A newly published article by Lee et al. provides a comparative analysis of dosimetric parameters of three radiation techniques for retro-orbital radiotherapy of patients with GO. The target coverage and dose sparing to adjacent normal structures was assessed in intensity modulated radiation therapy (IMRT), threedimensional conformal therapy (3DCRT), and lateral opposing fields (LOF). IMRT showed better target coverage, conformity, homogeneity and dose sparing to some surrounding structures than 3DCRT and LOF. Dosimetrically, it might be the preferable treatment technique of retro-orbital irradiation [35] .
Orbital radiotherapy -safety
Orbital radiotherapy might be connected to several side effects of tissue irradiation. The complications frequency increases with the radiation dose used. The extent of the normal tissue irradiation and the fractionation of the doses are also very important. The most common ocular side effects of radiotherapy are radiation retinopathy and optic neuropathy, respectively. Sometimes, radiation scleral necrosis appears, although it is far less frequent, probably due to radioresistance of the scleral collagen. These side effects can potentially cause blindness or even lead to enucleation of the eye [36] . Another quite frequently described complication is cataract. The EUGOGO, in its recently published statement, pointed out that severe hypertension or diabetic retinopathy is an absolute contraindication to orbital radiotherapy, whereas diabetes mellitus without retinopathy should be considered as a relative contraindication. Radiotherapy should not be used in young subjects (< 35 years) [11] .
Conclusions
Orbital radiotherapy remains an important method in the treatment of GO. Nevertheless, its appreciation has changed over the years. Currently, orbital irradiation seems to be a useful additional, second-line therapy that may significantly increase the efficacy of systemic PRACE POGLĄDOWE steroid treatment. However, due to the lack of unbiased, randomised prospective studies, the evaluation of true orbital radiotherapy efficacy is limited. In the era of evidence-based medicine, treatment standards cannot be established based on eight randomised and controlled studies. Nonetheless, orbital irradiation may be offered to patients with moderate-to-severe GO who have a poor response to routine therapy. Especially when the first course of steroid therapy has resulted in only a partial response and the disease remains active. The positive clinical outcome was observed mostly in eye motility and dysthyroid optic neuropathy improvement. It has to be noted that subsequent tissue fibrosis, as a result of irradiation, may prevent future treatment with high-dose glucocorticosteroids. Hence, rehabilitative eye surgery would be the eventual therapeutic strategy.
Nonetheless, more well-designed, multicentre, randomised, controlled studies enrolling large groups of subjects are inevitable in order to draw true conclusions about the applicability and efficacy of orbital radiotherapy in GO.
Polish version

Wstęp
Pierwszy opis choroby Gravesa-Basedowa (GD, Graves' disease) został zaprezentowany w 1835 roku przez dr. Roberta Jamesa Graves'a, jednak wielu innych badaczy, takich jak Karl Adolph von Basedow, zauważyło znacznie wcześniej charakterystyczne współwystępo-wanie takich cech jak wytrzeszcz gałek ocznych oraz powiększenie tarczycy [1] . Na przestrzeni lat wiedza o tej jednostce chorobowej, jej objawach oraz patomechanizmie uległa znacznemu poszerzeniu. Choroba Gravesa-Basedowa należy do chorób o podłożu
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autoimmunologicznym, podczas której dochodzi do produkcji przeciwciał wiążących się z receptorem dla TSH (TRAbs). Krążące przeciwciała stymulują receptory zlokalizowane w tarczycy oraz tkankach pozatarczycowych. W rezultacie powodują one hipertrofię tarczycy, mięśni oraz tkanki tłuszczowej oczodołu, wzrost syntezy hormonów tarczycy oraz pobudzają fibroblasty zlokalizowane w tkankach oczodołu do produkcji glikozaminoglikanów. Na pełny obraz choroby składają się objawy nadczynności tarczycy, wole, wytrzeszcz oraz wzrost stężenia TRAbs [2, 3] .
Najczęstszą pozatarczycową manifestacją choroby Gravesa-Basedowa jest orbitopatia (GO, Graves' orbitopathy). Występuje w 1,6 przypadków/milion populacji/na rok u płci żeńskiej oraz 0,29 przypadków/milion populacji/na rok u mężczyzn [4] . Według The European Group of Graves' Orbitopathy (EUGOGO), GO można podzielić na trzy grupy: orbitopatia grożąca utratą wzroku, postać umiarkowana oraz ciężka a także GO łagodna. Typ leczenia oraz zaklasyfikowanie do odpowiedniej grupy zależy od występujących objawów klinicznych oraz jakości życia pacjenta. W pierwszej grupie znajdują się pacjenci z wysokim ryzykiem ślepoty (neuropatia nerwu wzrokowego), u których natychmiast powinno być zastosowane leczenie. Druga grupa to pacjenci ze znacznym obniżeniem jakości życia oraz prezentujący dolegliwości ze strony gałek ocznych, takie jak: retrakcja powiek ≥ 2 mm, zwiększenie objętości tkanek miękkich w oczodole, wytrzeszcz ≥ 3mm oraz stałe lub okresowe podwójne widzenie. W grupie pacjentów z łagodną postacią GO wpływ choroby na jakość życia jest dużo mniejszy oraz nie występują cechy charakterystyczne dla umiarkowanej i ciężkiej GO. W tej grupie chorych leczenie zachowawcze jest wystarczające.
Leczenie GO jest z zasady wielokierunkowe, zależy od fazy choroby i polega na normalizacji funkcji tarczycy, modyfikacji czynników ryzyka (np. palenie tytoniu), suplementacji selenem, leczeniu immunosupresyjnym, chirurgicznym, radioterapii oraz połączeniu wszystkich tych metod [3] .
Leczenie łagodnej postaci GO
Niewątpliwie, najważniejszą kwestią w leczeniu postaci łagodnej GO jest normalizacja funkcji tarczycy oraz eliminacja czynników ryzyka. Poprzez właściwe leczenie nadczynności tarczycy ogranicza się aktywność choroby [5] . Najważniejszym czynnikiem ryzyka, który powinien zostać wyeliminowany jest palenie tytoniu. Palacze są 7-8-krotnie bardziej narażeni na rozwój choroby Gravesa-Basedowa, nasilenie GO jest większe i częściej dochodzi do progresja choroby. Ponadto, palacze są mniej podatni na leczenie niż osoby niepalące [6, 7] . Istnieją doniesienia, w których udowodniono korzyści związane z podawaniem selenu w trakcie leczenia GO, z uwagi na jego właściwości antyoksydacyjne [8] . Włączenie leczenia preparatami do stosowania miejscowego (np. sztuczne łzy) u pacjentów podających uczucie pieczenia i łzawienia gałek ocznych znacznie poprawia komfort życia. Szacuje się, że u około 15% pacjentów z łagodną postacią GO nastąpi progresja do umiarkowanej bądź ciężkiej postaci GO. Najsilniejszymi czynnikami wpływającymi na progresję i nasilenie GO są wysokie stężenie TRAb oraz palenie tytoniu [10] .
Leczenie umiarkowanej oraz ciężkiej postaci GO
Leczenie immunosupresyjne oraz immunomodulujące jest zarezerwowane dla pacjentów z GO, która znacząco wpływa na jakość ich życia oraz nie odpowiada na opisane wcześniej metody leczenia [11] . Leczenie z użyciem glikokortykosteroidów jest najskuteczniejsze w przypadku umiarkowanej oraz ciężkiej postaci GO. Pozytywną odpowiedź na leczenie uzyskano u blisko 80% badanych pacjentów [12, 13] . Obecnie, dożylne leczenie systemowe z użyciem prednizolonu jest uznawane za terapię pierwszego rzutu. Wysokie dawki prednizolonu stosowane dożylnie wykazały lepszą skuteczność kliniczną oraz mniejszy odsetek działań niepożądanych terapii, takich jak cukrzyca i wzrostu masy ciała, w porównaniu z terapią wysokimi dawkami doustnymi [14] . Po zakończeniu leczenia dożylnego zazwyczaj stosuje się kontynuację leczenia preparatami doustnymi lub domięśniowymi.
Inną metodą terapii GO jest leczenie analogami somatostatyny. Ponieważ receptory dla somatostatyny zostały wykryte na fibroblastach występujących w oczodole, wysnuto teorię o możliwej skuteczności tych preparatów w terapii GO. Obserwowano, że aktywność GO jest proporcjonalna do wychwytu znacznika w scyntygrafii oceniającej ekspresję receptorów dla somatostatyny (OctreoScan). Liczba przeprowadzonych dotychczas badań próbujących potwierdzić przydatność tej metody jest jednak niewielka, a wyniki niespójne [15] [16] [17] . Generalnie, użycie analogów somatostatyny powoduje niewielkie obniżenie aktywności GO, porównywalne z placebo, bez poprawy w zakresie innych objawów [18] . Toteż analogi somatostatyny nie są rutynowo używane w leczeniu GO.
Prummel i wsp. przeprowadzili badania nad efektywnością cyklosporyny w umiarkowanej oraz ciężkiej postaci GO. Efektywność leczenia cyklosporyną w porównaniu z leczeniem prednizolonem była gorsza. Jednak w grupie pacjentów, którzy otrzymali zarówno prednizolon, jak i cyklosporynę uzyskano lepsze wyniki terapii niż u pacjentów stosujących wyłącznie jeden
